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Background/aim: A post-marketing surveillance (PMS) study is being conducted to investigate the safety and
effectiveness of the long-term use of dabigatran etexilate (dabigatran) in Japanese patients with nonvalvular
atrial ﬁbrillation (NVAF). Results of an interim analysis of this prospective cohort study including patient
characteristics and adverse drug reactions (ADRs) collected up to September 17, 2014 are reported here.
Methods: Patients with NVAF who began to receive dabigatran for the ﬁrst time from December 2011 to
November 2013 were enrolled at 1042 study sites in Japan. Clinical parameters included patient char-
acteristics, dabigatran dose strength, concomitant medications and outcome events. All outcome events
were collected as serious and non-serious adverse events (AEs). ADRs were evaluated in this report. Pre-
deﬁned safety events of special interest for intensive survey were serious and non-serious outcome events
such as myocardial infarction, as well as the total number of hemorrhage and gastrointestinal disorders.
Results: A total of 6772 patients were registered. The safety analysis set included 6148 patients; mean age
was 70.879.9 (SD) years: 2323 patients (37.8%) were aged 75 years or older. Males accounted for 66.8% of
the patients. Mean CHADS2 score was 1.871.3; the CHADS2 score was 0 in 13.6%, 1 in 31.3%, 2 in 25.9%, 3 in
14.9%, and 4 to 6 in 11.1% of the patients. Of the 6148 patients, 1701 patients (27.7%) were switchers from
warfarin and 4407 patients (71.7%) were non-switchers (OAC naïve patients). Treatment adherence was
assessed for the ﬁrst 3 months from the start of treatment for this analysis. Total 5656 patients (92.0%)
reported taking dabigatran twice daily (bid) every day according to the label recommendation. During the
follow up period [mean duration of follow up: 4987259 days (corresponding to 8386 patient-years)], pre-
deﬁned safety events of special interest for intensive survey (reported as serious ADRs) were: myocardial
infarction, reported in 5 patients (0.06 per 100 patient-years); serious hemorrhage, reported in 46 patients
(0.55 per 100 patient-years); and gastrointestinal disorders (non-hemorrhagic), reported in 11 patients (0.13
per 100 patient-years). Fifteen patients had ADRs with fatal outcome.
Conclusions: The interim ﬁndings from this 6148 patient PMS study further corroborate the favorable safety
proﬁle of dabigatran as demonstrated previously in controlled clinical trials.
(ClinicalTrials.gov number, NCT01491178.)
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).blished by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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noue).
H. Inoue et al. / Journal of Arrhythmia 32 (2016) 145–1501461. Introduction
Atrial ﬁbrillation (AF) is an arrhythmia that is commonly seen
and occurs more often in the elderly. In Japan, the overall pre-
valence of all types of AF based on the data from periodic health
examinations was estimated to be 0.56% [1]. Considering the aging
population in Japan, it is estimated that more than 1 million
individuals would be suffering from the disease in the year 2030.
The number of AF patients would increase when patients with
paroxysmal AF are included. Nonvalvular atrial ﬁbrillation (NVAF)
associated with lifestyle-related diseases, such as hypertension
and diabetes mellitus, is predominant among the patient popula-
tion [1].
For the prevention of stroke in NVAF patients, appropriate antith-
rombotic therapy should be selected after a risk assessment of cerebral
infarction [2]. In the past, warfarin was the only anticoagulant drug
indicated for NVAF in Japan but less than 60% of high-risk NVAF
patients are treated with the drug in real-world practice [3]. The major
reason for under-use of warfarin is the difﬁculty in controlling antic-
oagulation intensity: it requires dose adjustments by routine mon-
itoring of prothrombin time-international normalized ratio (PT-INR)
because of its narrow therapeutic range, and it is subject to pharma-
codynamic and pharmacokinetic interactions with concomitant drugs
and diet.
Dabigatran etexilate (dabigatran) has been developed as a new
anticoagulant (non-vitamin K antagonist oral anticoagulant;
NOAC) to solve the above issues. Dabigatran is a direct competitive
inhibitor of thrombin, which is the critical factor in the blood-
clotting cascade, thereby suppressing the conversion of ﬁbrinogen
to ﬁbrin, and leading to the prevention of thrombosis [4].
In the RE-LY study [5], a randomized global phase III study,
which included Japanese patients, the favorable efﬁcacy and safety
of dabigatran compared to that of INR-adjusted warfarin was
demonstrated. The Japanese Guidelines for Pharmacotherapy of AF
(revised in 2013) [6] recommend dabigatran for NVAF patients
whose CHADS2 scores are 1 or higher, taking into account the
overall results of the RE-LY study and its sub-analysis, showing the
efﬁcacy and safety of dabigatran for patients with CHADS2 score of
1 or higher. In the United States [7] and Denmark [8,9], large-scale
investigations performed by the FDA and independent academic
institutions, respectively, have meanwhile conﬁrmed the effec-
tiveness and safety of dabigatran in the real world.
In Japan, a post-marketing surveillance (PMS) study was star-
ted in December 2011 to investigate the safety and effectiveness of
the long-term use of dabigatran in real-world practice; more than
6700 patients were enrolled. The aim of this ongoing prospective
PMS study is to survey the safety and effectiveness of the long-
term use of dabigatran in NVAF patients who receive dabigatran
for the ﬁrst time. It is conducted in compliance with “The Law on
Securing Quality, Efﬁcacy and Safety of Products including Phar-
maceuticals and Medical Devices” (Law Number: Act No. 145 of
1960) and “Good post-marketing surveillance practice (GPSP)”
(Japanese Ministry of Health and Welfare Ordinance No. 171:
December 20, 2004). The interim analysis results of the PMS study
collected up to September 17, 2014 are reported herein.2. Material and methods
2.1. Subjects
Patients with NVAF who started dabigatran treatment from
December 12, 2011 to November 30, 2013 were registered at 1042
study sites in Japan. This report is based on the data from the case
report forms (CRFs) collected up to September 17, 2014.2.2. Study methods
Electronic data capture system was used for the collection of
data on demographics, clinical characteristics, dabigatran treat-
ment status, concomitant medications, adverse events (AE), and
adverse drug reactions (ADR; which are events with at least rea-
sonably possible causal relationship with dabigatran) including
outcome events of speciﬁc interest. In this report, ADRs out of the
AEs reported are summarized. CHADS2 score [2] was calculated
based on the patient conditions: congestive heart failure/left
ventricular dysfunction, hypertension, age (Z75 years), diabetes
mellitus, and previous stroke/transient ischemic attack. Myo-
cardial infarction, hemorrhage, and gastrointestinal disorders were
selected as the non-serious or serious safety events of special
interest for intensive survey. Hemorrhage included all the serious
and non-serious hemorrhagic events reported in the CRF. The
following criteria were applied for major hemorrhage: sympto-
matic hemorrhage in a critical area or organ, such as intracranial,
intramedullary, intraocular, retroperitoneal, intra-articular, and
pericardial hemorrhage, and intramuscular hemorrhage with
muscular compartment syndrome; hemorrhage with decrease in
hemoglobin of 2 g/dL or more; and major hemorrhage requiring
5 units or more of blood transfusion (blood component transfusion
of red blood cells or whole blood transfusion). Among any unto-
ward medical events, the following AEs and ADRs were deﬁned as
“serious”: those that resulted in death, life-threatening events,
those requiring hospitalization or prolongation of hospital stay,
those that resulted in persistent or signiﬁcant disability/incapacity,
or congenital anomalies/birth defects. The exposure of each
patient was the reported treatment duration if documented in the
CRF or calculated from the ﬁrst dabigatran treatment prescribed
until September 17, 2014.
Patients who used warfarin within 7 days before the start of
dabigatran treatment were deﬁned as “Switchers (warfarin-
experienced)”, and those who did not use warfarin within that
period as “non-Switchers (warfarin-naïve)”.
Patients were followed for a maximum of 24 months from the
index date (start of treatment). The CRFs were completed at the
following time points: at baseline, before the start of dabigatran
administration, and at 3 and 24 months after the start of treatment,
at the time of serious ADR occurrence or at the time of dis-
continuation/dropout. The survey will continue until March 2016.
AEs reported in the study were handled as solicited reports. At
the time of the interim analysis of this study, the drug exposure
has been estimated based on all the data available at the cutoff
date of the analysis. Final analysis at the end of the study will
report the actual exposure based on all the data available.
2.3. Statistical analysis
Descriptive statistical methods were used for analyses. Data are
expressed as mean7standard deviation (SD) or percentage.3. Results
3.1. Clinical background
A total of 6772 patients were registered in the PMS study. The
ﬁnal sample size for this analysis included a total of 6148 patients,
excluding those who were ineligible for registration or who did
not visit the site after the ﬁrst visit (Fig. 1). Three-month follow-up
was completed in 6324 patients, and 24-month follow-up in 1213
patients.
Baseline demographics and clinical characteristics are shown in
Table 1 (more detailed backgrounds are provided in the
Table 1
Patient characteristics (safety analysis set).
Variable Initial daily dose of dabigatran
etexilate
Totala (n¼6148)
220 mg
(n¼4560)
300 mg
(n¼1473)
Age, years 73.278.7 63.079.0 70.879.9
o65 666 (14.6) 791 (53.7) 1467 (23.9)
65–74 1747 (38.3) 577 (39.2) 2358 (38.4)
Z75 2147 (47.1) 105 (7.1) 2323 (37.8)
Z70 3295 (72.3) 295 (20.0) 3680 (59.9)
Women 1697 (37.2) 293 (19.9) 2044 (33.2)
Creatinine clearance, mL/min
o30 28 (0.6) 6 (0.4) 38 (0.6)
30–50 925 (20.3) 37 (2.5) 1006 (16.4)
50o to o80 2314 (50.7) 505 (34.3) 2859 (46.5)
Z80 1082 (23.7) 854 (58.0) 1953 (31.8)
Unknown 211 (4.6) 71 (4.8) 292 (4.7)
mean7SD 67.6723.0 89.8727.6 72.8726.1
CHADS2 score
0 517 (11.3) 309 (21.0) 839 (13.6)
1 1333 (29.2) 561 (38.1) 1923 (31.3)
2 1237 (27.1) 319 (21.7) 1594 (25.9)
3 731 (16.0) 171 (11.6) 919 (14.9)
4 422 (9.3) 63 (4.3) 497 (8.1)
5 139 (3.0) 14 (1.0) 156 (2.5)
6 30 (0.7) 0 (0.0) 30 (0.5)
Unknown 151 (3.3) 36 (2.4) 190 (3.1)
mean7SD 1.971.3 1.471.1 1.871.3
Previous history
Stroke/TIA 924 (20.3) 273 (18.5) 1218 (19.8)
Myocardial infarction 233 (5.1) 46 (3.1) 283 (4.6)
Hemorrhagic events 243 (5.3) 35 (2.4) 289 (4.7)
Gastrointestinal
hemorrhage
66 (1.4) 9 (0.6) 77 (1.3)
Gastrointestinal
disorder
101 (2.2) 37 (2.5) 142 (2.3)
Comorbidity
Heart failure 863 (18.9) 215 (14.6) 1105 (18.0)
Hypertension 3070 (67.3) 908 (61.6) 4054 (65.9)
Diabetes mellitus 925 (20.3) 297 (20.2) 1236 (20.1)
Liver function disorder 445 (9.8) 160 (10.9) 612 (10.0)
Renal impairment 1934 (42.4) 279 (18.9) 2279 (37.1)
Gastrointestinal
disorder
720 (15.8) 154 (10.5) 887 (14.4)
Concomitant use of
antiplatelets
508 (11.1) 108 ( 7.3) 635 (10.3)
TIA: transient ischemic attack.
Values are number (%) or mean7standard deviation.
a Including 115 patients who received other dose levels.
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(37.8%) were aged 75 years or older. Of those, 4104 patients (66.8%)
were male. CHADS2 score of 1 was the most common among the
patients (Supplementary Fig. 1). Hypertension was the most
common comorbidity followed by renal impairment. A creatinine
clearance (ClCr) of “50o to o80 mL/min” was seen most fre-
quently (50.7%) in patients receiving 220 mg/day; whereas
“Z80 mL/min” was seen most frequently (58.0%) in patients
receiving 300 mg/day. ClCr of “30–50 mL/min” was seen in 1006
patients, which is the dose chosen (220 mg/day or 300 mg/day)
criteria of dabigatran. Indeed, 925 (91.9%) of 1006 patients were
administered 220 mg/day of the drug. There were 38 patients
whose ClCr was “o30 mL/min”, a contraindication level for dabi-
gatran use; nevertheless, most of them (n¼28, 73.7%) were
administered 220 mg/day of dabigatran (Supplementary Fig. 2).
The initial daily dose of dabigatran was 220 mg/day (110 mg
twice daily) in approximately three-fourths of the patients, less
than 220 mg/day in 109 patients (1.8%) and more than 300 mg/day
(150 mg twice daily) in 6 patients (0.1%). Seventy years or older is
the age cut-off for a dose reduction to 220 mg/day in the Japanese
label. Indeed, 3295 (89.5%) of 3680 patients were administered
220 mg/day of dabigatran. Among the 2468 patients aged less than
70 years, only 47.7% were administered 300 mg/day of dabigatran.
Antiplatelet agents were used concomitantly in 10.3% of the
patients.
Treatment adherence was assessed for the ﬁrst 3 months from
the start of treatment for this analysis. 5656 Patients (92.0%)
reported taking dabigatran every day for 3 months from the start
of administration. The dosage of dabigatran did not affect the
medication adherence (Table 2).
3.2. Clinical background of Switchers and non-Switchers
Switchers from warfarin were 1701 patients (27.7%), non-
Switchers were 4407 patients (71.7%) and for 40 patients (0.7%)
this is unknown. A CHADS2 score of 2 or more and permanent AF
were more common in Switchers than in non-Switchers
(Figs. 2 and 3).
3.3. Safety
During the mean follow up period of 4987259 days (8386
patient-years), the serious and non-serious ADRs of special inter-
est for intensive survey were myocardial infarction in 5 patients
(0.06 per 100 patient-years), serious hemorrhages in 46 patients
(0.55 per 100 patient-years), and gastrointestinal disorders (non-
hemorrhagic) in 11 patients (0.13 per 100 patient-years). SeriousRegistered 6,772
Not collected case report form (CRF) 448
Not sent 372
Not collectible 76
Excluded from the safety analysis set 176
Registration violation 30
No visit after the first consultation 146
Collected CRF for 
Safety analysis set 6,148
Fig. 1. Patient disposition.
Table 2
Medication adherence (3-month follow-up).
Initial daily dose of dabigatran etexilate Total (n¼6148)
220 mg
(n¼4560)
300 mg
(n¼1473)
Others
(n¼115)
Completely
taken
4218 (92.5) 1332 (90.4) 106 (92.2) 5656 (92.0)
Often taken
(Z2/3)
165 (3.6) 81 (5.5) 3 (2.6) 249 (4.1)
Sometimes
taken (Z1/3
to o2/3)
24 (0.5) 13 (0.9) 1 (0.9) 38 (0.6)
Rarely taken
(o1/3)
26 (0.6) 5 (0.3) 1 (0.9) 32 (0.5)
Unknown 127 (2.8) 42 (2.9) 4 (3.5) 173 (2.8)
Values are number (%).
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Fig. 2. Distribution of CHADS2 score by use status of warfarin experience prior to
dabigatran treatment (black¼Switchers, white¼non-Switchers).
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Fig. 3. Type of atrial ﬁbrillation by use status of warfarin experience prior to
dabigatran treatment (black¼Switchers, white¼non-Switchers).
Table 3
Serious adverse drug reactions (ADRs).
Safety analysis set n¼6148
Follow-up period, mean7SD, days 4987259
Cumulative exposure, patient-years 8386
Safety events of special interest for
intensive survey
No. of patients Per 100 patient-
years
Myocardial infarction 5 0.06
Serious hemorrhage 46 0.55
Gastrointestinal disordera (non-
hemorrhagic)
11 0.13
Details of serious hemorrhage No. of patients Per 100 patient-
years
Total serious hemorrhagic events 46 0.55
Gastrointestinal hemorrhagesb 26 0.31
Upper gastrointestinal hemorrhage 15 0.18
Lower gastrointestinal hemorrhage 12 0.14
Melena 1 0.01
Intracranial hemorrhages 10 0.12
Subdural hematoma 5 0.06
Intracerebral hemorrhage 4 0.05
Subarachnoid hemorrhage 1 0.01
Others 10 0.12
a Classiﬁed by MedDRA SOC cords.
b Some events are counted in more than one category.
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patients (0.31 per 100 patient-years), intracranial hemorrhages in
10 patients (0.12 per 100 patient-years), and other hemorrhages in
10 patients (0.12 per 100 patient-years) (Table 3). In spite of con-
traindication (ClCro30 mL/min), one gastrointestinal hemorrhage
was observed in a patient who received 220 mg/day. Fifteen
patients (0.18 per 100 patient-years) had ADRs with fatal outcome.
The causes of fatal outcome (in 15 patients) were as follows:
hemorrhages in 4 patients (aortic aneurysm rupture, intracerebral
hemorrhage, subdural hematoma, and gastrointestinal hemor-
rhage in 1 patient for each), cerebral infarction in 2 patients,
pneumonia in 1 patient, anoxic encephalopathy in 1 patient, and
cause of death unknown in 7 patients.4. Discussion
This PMS study is a long-term, large-scale, prospective, non-
interventional study in NVAF patients who received dabigatran for
the ﬁrst time in Japan, which is being conducted as a special drug
use survey based on the law of Japan and the Ordinance of the
Ministry of Health, Labor and Welfare. It is so far the largest of its
kind for an NOAC registered in Japan.
Switchers had a higher risk of stroke with a CHADS2 score of at
least 2, whereas non-switchers mostly had a CHADS2 score of 0 or
1. Permanent AF was most common in Switchers, whereas par-
oxysmal AF was most common in non-Switchers. Medicationadherence was good with 490% measured for the ﬁrst 3 months
of treatment period.
In the RE-LY study [5], patients with a CHADS2 score of
2 accounted for the highest proportion of about 35%; in the Asian
subgroup [10] in particular, patients with CHADS2 scores Z3
accounted for 36.8%. In the present PMS study, however, patients
with CHADS2 scores of 0 or 1 accounted for 44.9%, indicating that
more NVAF patients at a lower risk for stroke were observed in
real clinical practice than in the RE-LY study.
The J-RHYTHM Registry [11], which is a Japanese non-
interventional study, showed quite comparable risk scores at
baseline for stroke [mean CHADS2 score: 1.871.3 (this study) vs.
1.771.2; proportion of patients with CHADS2 scores of 0 or 1:
44.9% and 49.6%, respectively]. The Fushimi AF Registry [12] is a
non-interventional study to enroll AF patients in Fushimi-ku,
Kyoto that is assumed to represent a typical urban community in
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proportion of patients with CHADS2 scores of 0 or 1 was lower at
36.9% in the Fushimi AF Registry than in the present study.
According to the labeling of dabigatran in Japan, patients to be
considered for the prescription of the lower dose of 220 mg/day
are as follows: (1) aged Z70 years, (2) with moderate renal
impairment (ClCr 30–50 mL/min), (3) concomitant use of a p-
glycoprotein inhibitor, and (4) history of hemorrhage or hemor-
rhagic tendency. In the present study, 89.5% of the patients aged
Z70 years used the low dose (220 mg/day), whereas only 53.9% of
the patients aged o65 years and 47.7% of the patients aged o70
used the higher dose (300 mg/day) of dabigatran. This suggests
that low-dose administration is preferably selected regardless of
the dosage chosen criteria for age in the label (Table 1).
Low dose of dabigatran was given to 91.9% of the patients with
ClCr levels of 30–50 mL/min, and also used in 84.9% of the patients
diagnosed with renal impairment as comorbidity (Table 1). Of
note, 38 patients with ClCr levels of o30 mL/min were adminis-
tered dabigatran despite contraindication.
Among the patients with a history of hemorrhage, 84% were
administered the low-dose, whereas 12% were administered the
high-dose of dabigatran (Table 1). As described above, low-dose
administration was selected for more patients (85–90% or more)
than recommended in the labeling of dabigatran.
There are several limitations to the present interim analysis. All
the results are based on an interim analysis performed on the data
obtained from 6148 patients with a mean follow-up period of 498
days. Safety events will be reported in the ﬁnal analysis of the
study. Medication adherence was assessed by the individual
treating doctors, and was not assessed quantitatively.
The period of this interim analysis study is longer than the
published periods for other NOACs, also reﬂecting the fact that
dabigatran was the ﬁrst launched NOAC in Japan. The PMS study
will be continued until March 2016 and the ﬁnal analyses on the
safety and effectiveness are due to be reported.5. Conclusions
The selected dosage of dabigatran is chosen predominantly in
accordance with the label recommendation. The main prescribed
dosage strength is 220 mg/day of dabigatran. The assessment of
predeﬁned serious safety outcomes for intensive survey revealed
an incidence of myocardial infarction of 0.06 per 100 patient-years
and 0.55 per 100 patient-years for serious hemorrhage, and 0.13
per 100 patient-years for gastrointestinal disorders. Among NVAF
patients newly treated with dabigatran or those switching from
warfarin to dabigatran, the favorable safety proﬁle of dabigatran,
as demonstrated previously in randomized clinical trials, is cor-
roborated in the real world setting in Japan.Source of funding
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